Neko Health Launches First U.S. Office in New York Under Daniel Ek – A New Era for Health‑Scanning

Spotify co‑founder Daniel Ek is planting a flagship in the heart of New York’s health‑scanning arena.

Prime Soho Address: 300 Lafayette Street

■Neko Health will open its U.S. headquarters on September 24 at 300 Lafayette Street, Manhattan’s upscale Soho district.

■The location offers high visibility and proximity to affluent clientele, a strategic advantage for premium health services.

■The company reports a 25,000‑person waitlist from New Yorkers eager for early access.

Funding Engine: $700 Million Series C and Aggressive Growth Targets

■A $700 million Series C round closed last month, marking Neko’s largest capital raise to date.

■To date, 100,000 individuals have undergone scans; the firm aims to lift that figure to 500,000 within two years.

■Existing sites in the U.K. and Sweden will be complemented by the U.S. launch, tripling the company’s global footprint.

Competitive Landscape: Tech Titans and Longevity Ventures

■Midjourney, famed for its AI image models, is also building a body scanner slated for a 2027 San Francisco spa rollout.

■Tony Robbins and Peter Diamandis back Fountain Life, another longevity‑focused health‑assessment platform.

■Function Health, co‑founded by wellness podcaster Dr. Mark Hyman, secured a $450 million loan to acquire Ezra and add body‑scan services to its suite.

Markets view this move as a natural extension of the digital‑health and data‑analytics growth narrative. Neko Health’s New York foothold grants direct access to high‑spending consumers, potentially reshaping venture‑capital allocations toward “longevity” and preventive‑health startups. While VCs are gravitating toward this niche, Neko’s strong brand and founder pedigree could spark a SPAC‑style pre‑IPO or a direct listing. In the short term, the office opening is likely to lift regional demand and partnership pipelines, prompting a 30‑40% upward revision of revenue forecasts; over the medium term, the integration of its data platform with biotech partners will be a critical catalyst for expanding market share.